Gienoe (Sofosbuvir,Velpatasvir)

$1 / Price
  • Brand Name:
  • Origin:
  • Small Orders:
    50 Bottles
  • Tags:
Inquire Now Link

  • Details
  • Description
  • Packaging Size
  • Strength
  • Compositon
  • Treatment
    hepatitis C
  • Form
  • Brand
  • Quantity Unit
    400mg&100mg/T, 28T/Bottle
  • Manufacturer
    Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.

Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS. It is taken by mouth.

In March 2020, sofosbuvir/velpatasvir was approved for use in the United States to treat hepatitis C virus (HCV) in children ages six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis. Sofosbuvir/velpatasvir in combination with ribavirin is indicated for the treatment of children six years and older or weighing at least 37 pounds with severe cirrhosis.

The combination is generally well tolerated. Common side effects include headaches, fatigue, trouble sleeping, and nausea. The combination has not been studied in pregnant women or during breastfeeding. Greater care is required in those who are also infected with hepatitis B. Sofosbuvir works by blocking the NS5B protein and velpatasvir works by blocking the NS5A protein.

Sofosbuvir/velpatasvir was approved for medical use in the United States and in Europe in 2016.It is on the World Health Organization's List of Essential Medicines.

Medical uses
A single tablet regimen is used for adults with genotype 1–6 chronic hepatitis C virus (HCV) infection.

Why is this medication prescribed?
The combination of sofosbuvir and velpatasvir is used alone or with ribavirin (Copegus, Rebetol, Ribasphere) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in adults and children 6 years of age and older or who weigh at least 37 lbs (17 kg). Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors. The combination of sofosbuvir and velpatasvir works by stopping the virus that causes hepatitis C from spreading inside the body.

How should this medicine be used?
The combination of sofosbuvir and velpatasvir comes as a tablet to take by mouth. It is taken usually with or without food once a day for 12 weeks. Take sofosbuvir and velpatasvir at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take sofosbuvir and velpatasvir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Continue to take sofosbuvir and velpatasvir even if you feel well. Do not stop taking sofosbuvir and velpatasvir without talking to your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What side effects can this medication cause?
Sofosbuvir and velpatasvir may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
lack of energy
feeling irritable
feeling depressed
Sofosbuvir and velpatasvir may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.